PET/CT评估免疫检查点抑制剂肿瘤应答专家共识(2020版)
免疫检查点抑制剂(ICIs)治疗可出现假性进展、超进展等特殊应答模式,给疗效评价带来困难。本共识由中华医学会核医学分会PET学组牵头,针对PET/CT检查规范、ICIs治疗后图像解读及疗效评价标准,结合文献、专家经验和委员会内部讨论达成,以期规范并推广PET/CT在肿瘤免疫治疗评价中的应用。
要点
- ICIs治疗可出现假性进展、超进展等特殊应答模式,影响疗效评价。
- 共识聚焦PET/CT检查规范、图像解读及ICIs治疗后疗效评价标准。
- 由中华医学会核医学分会PET学组牵头,结合文献与专家经验达成。
核心结论
- 共识旨在规范PET/CT在肿瘤ICIs治疗应答评价中的应用并推动技术普及。
研究设计与样本
- 由中华医学会核医学分会PET学组牵头制定,结合文献、专家经验和委员会成员内部讨论形成共识。
主要发现
- ICIs因作用机制可出现假性进展、超进展等特殊应答模式,对临床治疗决策和疗效评价带来困难与挑战。
- 2017年欧洲核医学年会根据已公布临床试验数据报道了应用18F-FDG PET/CT评价肿瘤免疫治疗反应和判读免疫相关不良反应的优势。
- 中国自2013年正式开始ICIs临床研究以来已产生大量研究数据。
关键数值与推荐
- 共识针对PET/CT检查规范、ICIs治疗后PET/CT图像解读、疗效评价标准等内容形成推荐。
临床怎么用
- 在肿瘤ICIs治疗中合理、规范地应用PET/CT进行疗效评价和免疫相关不良反应判读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Immune checkpoint inhibitors (ICIs) have represented a major breakthrough in the field of malignant tumor treatment. However, due to the mechanism of this novel therapy, some special forms of response modes, such as pseudoprogression and hyperprogression, have arisen, which bring difficulties and challenges to the therapeutic efficacy evaluation. In 2017, the European association of nuclear medicine reported the advantages of using 18-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT to evaluate the tumor immunotherapy response and immune-related side effects based on the published clinical trial data. In China, a large amount of research data has been generated since the clinical study of immune checkpoint inhibitors officially started in 2013.Therefore, how to utilize PET/CT reasonably and standardly in tumor immunotherapy has become an urgent clinical and scientific issue. Focusing on the practical questions of examination procedures, PET/CT image interpretation and the evaluation criteria after ICIs treatment, this consensus has been finally formed, which based on the combination of literature, expert experiences, and internal discussion among committee members in the PET Group of Chinese Society of Nuclear Medicine.This consensus is also expected to improve the guide for standardizing the application of PET/CT to evaluate tumor immunotherapy response and promoting the technology in corresponding field. 免疫检查点抑制剂(ICIs)是恶性肿瘤治疗领域的重大突破,但由于其作用机制使然,出现了假性进展、超进展等特殊肿瘤应答模式,对临床治疗决策和疗效评价带来了困难与挑战。2017年,欧洲核医学年会根据已公布的临床试验数据,报道了应用(18)F-FDG PET/CT评价肿瘤免疫治疗反应、判读免疫相关不良反应的优势。在中国,自2013年正式开始ICIs的临床研究以来,已有大量的研究数据产生,如何在肿瘤ICIs治疗中合理、规范地应用PET/CT成为亟待解决的临床和科学问题。鉴于此,由中华医学会核医学分会PET学组牵头,针对PET/CT检查规范、ICIs治疗后PET/CT图像解读、疗效评价标准等内容,在结合文献、专家经验和委员会成员内部讨论的基础上,最终达成此共识,以期带动相应领域的技术普及与推广。.
引用
- [Expert consensus on assessing tumor response to immune checkpoint inhibitors by PET/CT (2020 Edition)]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32988149. doi:10.3760/cma.j.cn112152-20200623-00590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。